In response to the stated NIAID growing need for expertise in the area of vaccine research and development, the medical research community at the University of Pennsylvania proposes to establish a training program in Vaccines and Immune Therapeutics. The University Campus has an important history of contribution to vaccine discovery, development and testing of many currently licensed vaccines and has developed an important program to share this expertise with trainees. Trainers are drawn from the Wistar Institute, University of Pennsylvania, as well as the Children's Hospital of Philadelphia, which are institutions located contiguously on the University of Pennsylvania campus. The training program would initially support 3 students among a pool of Ph.D or MD/Ph.D or V.M.D./Ph.D candidates, as well as 1 post doctoral fellow. This application would allow the trainees to train in one of 21 laboratories directed by highly motivated Principal Investigators who have established records in training in important areas of Vaccine and Immune Therapy research. The trainers associated with this T32 application were selected based on their well established record of accomplishment in Vaccine/Immune Therapy-related research as evidenced by their reputations, strong publication records and grant funding, as well as a strong group history of minority training and recruitment and strong reviews for participation in student training. This training program will be part of the newly defined graduate training program in Gene Therapy and Vaccines (GTV), which is one of the 6 programs in the Cell and Molecular Biology Graduate Program (CAMB). The affiliation with CAMB, the largest biomedical graduate training program at the University of Pennsylvania, will facilitate student training and stability on the campus. Furthermore a unique externship relationship with industry allows students and postdoctoral trainees to experience training at some of the nations elite company vaccine settings in a highly formalized manner. The GTV training program has formal mechanisms to monitor trainees'progress both during and after their training grant support. Specialized courses have been developed and are in place to ensure significant grounding in Vaccines and Immune Therapy. An exceptional group of faculty has been assembled to assist in this process. Importantly, the training program has formal mechanisms to monitor trainers and to ensure a high level of accomplishment for trainees and faculty alike.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Institutional National Research Service Award (T32)
Project #
5T32AI070099-05
Application #
8286982
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Mcsweegan, Edward
Project Start
2008-07-01
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
5
Fiscal Year
2012
Total Cost
$197,623
Indirect Cost
$10,791
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Leskowitz, R; Fogg, M H; Zhou, X Y et al. (2014) Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques. J Virol 88:4721-35
Abdulhaqq, Shaheed A; Martinez, Melween I; Kang, Guobin et al. (2014) Serial cervicovaginal exposures with replication-deficient SIVsm induce higher dendritic cell (pDC) and CD4+ T-cell infiltrates not associated with prevention but a more severe SIVmac251 infection of rhesus macaques. J Acquir Immune Defic Syndr 65:405-13
Ferraro, B; Talbott, K T; Balakrishnan, A et al. (2013) Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. Infect Immun 81:3709-20
Leskowitz, R M; Zhou, X Y; Villinger, F et al. (2013) CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques. J Virol 87:8351-62
Shedlock, Devon J; Aviles, Jenna; Talbott, Kendra T et al. (2013) Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 21:1432-44
Bortnick, Alexandra; Chernova, Irene; Quinn 3rd, William J et al. (2012) Long-lived bone marrow plasma cells are induced early in response to T cell-independent or T cell-dependent antigens. J Immunol 188:5389-96
Shedlock, Devon J; Talbott, Kendra T; Cress, Christina et al. (2011) A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine 29:6755-62
Mallilankaraman, Karthik; Shedlock, Devon J; Bao, Huihui et al. (2011) A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 5:e928
Morrow, Matthew P; Yan, Jian; Pankhong, Panyupa et al. (2010) IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther 18:1714-23
Shedlock, Devon J; Talbott, Kendra T; Morrow, Matthew P et al. (2010) Ki-67 staining for determination of rhesus macaque T cell proliferative responses ex vivo. Cytometry A 77:275-84

Showing the most recent 10 out of 13 publications